Download our whitepaper,
"Amyotrophic Lateral Sclerosis (ALS): Exploring Diagnostic Criteria, Drug Development, and Clinical Trial Challenges"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for ALS Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for ALS.
- Comprehensive Analysis of FDA-Approved ALS Drugs.
- How Diagnostic Criteria for ALS Have Evolved and Impact Research.
- Overcoming Common Pitfalls in ALS Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
ALS Clinical Trials
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that primarily attacks motor neurons in the brain and the spinal cord. The disease leads to the gradual deterioration and eventual death of motor neurons, which are crucial for controlling voluntary muscles.
Navigating the regulatory landscape is critical for the success of clinical trials in ALS. The US FDA sets stringent standards to ensure that new treatments are safe and effective. Understanding these regulatory requirements and implementing strategies to meet them are essential steps in the development and approval process of new ALS treatments.
ALS is most commonly diagnosed between the ages of
40&70
ALS accounts for approximately
2%
of all neurogenerative disorders globally
ALS affects approximately
5
in 100,000 people worldwide annually
Our clinical team has over
120
years of combined clinical trial experience